Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company's oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60.

Create Account

Dark

chart

exchange

RTTNews | Mar 11, 2021 07:45AM EST

07:45 Thursday, March 11, 2021 (RTTNews.com) - Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company's oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60.

Fostamatinib is marketed in the U.S. as TAVALISSE tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia.

Rigel expects to report topline data from the clinical trial in April 2021.

Read the original article on RTTNews ( https://www.rttnews.com/3176705/rigel-completes-patient-enrollment-in-phase-2-trial-to-evaluate-fostamatinib-in-covid-19-patients.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved